CTOs on the Move

Id Labs Inc

www.idlabs.com

 
Id Labs Inc is a London, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.idlabs.com
  • PO Box 1145 Stn B
    London, ON CAN N6A 5K2
  • Phone: 519.434.5057

Executives

Name Title Contact Details

Similar Companies

Provident Clinical Research and Consulting

Provident Clinical Research and Consulting, Inc. is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Palleon Pharmaceuticals

Palleon is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.

Merrimack Pharmaceuticals

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack has multiple oncology therapeutics in clinical development and additional candidates in late stage preclinical development. Merrimack has a New Drug Application under review for its lead product candidate, MM-398, for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.

Labviva

Revolutionizing life sciences procurement. AI-powered digital marketplace for complete transparency into your supply chain Labviva integrates with your existing purchasing software to provide you with actionable insights to make better decisions. Keep your current suppliers, contract pricing, and your purchasing software and processes. Our digital marketplace offers unparalleled visibility into your procurement process, to empower informed decisions to drive science forward without interruptions to your research.

Slingshot Biosciences

Making advanced diagnostics and adoptive cell therapies more accessible by working from the bottom up via synthetic cells.